Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer
Women in this age category qualify for clinical genetic testing and magnetic resonance imaging screening
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab
Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer
FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma
The approval concerns management of patients with no MSI-H/dMMR tumours
Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant Neurocognitive Decline
Findings from a prospective study from the St Jude Lifetime Cohort
Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma
Results of the second interim analysis of the KEYNOTE-629 study
Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab
The results of a phase II study in patients with recurrent mismatch repair deficient and/or microsatellite instability-high endometrial cancer
FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease
Evidence for efficacy is based on the results from KD025-213 study
Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies
Coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in patients with haematological malignancies
Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy
Findings from the STHLM3-MRI population-based prostate cancer screening study by invitation
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple Myeloma
Evidence for efficacy is based on the results from the APOLLO study
FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma
Evidence for efficacy is based on the results from the Study JZP458-201
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
Evidence is based on the results from the EV-301 study that was required to confirm the clinical benefit of the 2019 accelerated approval